Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
5
×
boston top stories
life sciences
national blog main
san francisco blog main
boston
clinical trials
deals
national top stories
new york blog main
new york top stories
san francisco top stories
startups
third rock ventures
vc
abbvie
acetylon pharmaceuticals
allergan
ally bridge group
alzheimer's disease
ambys medicines
azacitidine
beta-thalassemia
big data analytics
black diamond therapeutics
blackrock
bladder cancer
blueprint medicines
cancer
cancer drugs
casdin capital
cell therapy
constellation pharmaceuticals
crispr
cynthia collins
dacogen
deciphera pharmaceuticals
decitabine
diabetic nephropathy
What
biotech
5
×
medicines
5
×
new
research
diseases
drug
genetic
ipo
lead
startup
therapeutics
abbvie
aiming
aims
alliance
ambys
analysis
approach
based
big
bio
black
bring
called
cancer
clinic
companies
company
control
deadly
deal
debuted
debuts
develop
developing
diamond
drugs
editas
editing
eluded
Language
unset
Current search:
biotech
×
medicines
×
" boston blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
